RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

计划入组 60 人 · 首次发布于 2022 年 10 月 31 日

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

计划入组 88 人 · 首次发布于 2022 年 6 月 22 日

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

计划入组 6 人 · 首次发布于 2010 年 12 月 31 日

Selexipag(Uptravi, Uptravi Titration Pack)

C₂₆H₃₂N₄O₄S · Rx

Prostacyclin analog (CoNCERT)

Epoprostenol(Flolan, Veletri)

C₂₀H₃₂O₅

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Veru Inc

United States

Insmed's Treprostinil Palmitil Shows Promise for Rare Pulmonary Disorders with Projected $66M Revenue by 2037

Cereno Scientific Reports Promising Phase IIa Results for CS1 in Pulmonary Arterial Hypertension

United Therapeutics' Ralinepag Achieves 55% Risk Reduction in Pivotal PAH Trial, Paving Way for FDA Submission